Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 1556

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 1556
---
 Mr. Knuettel and his wife are co-trustees (the “Knuettel Trust”), and at no charge to them, additional non-transferable
Subscription Rights to purchase up to an aggregate 158,731 shares of our Common Stock in the Rights Offering at the same Subscription
Price. On December 27, 2023, the Knuettel Trust made a charitable donation of 27,778 of those shares to Temple Israel of the City
of New York. On June 28, 2024, the Knuettel Trust made an additional charitable donation of 5,000 shares to Temple Israel of the
City of New York and 15,000 shares to The Hewitt School. Also on December 27, 2023, AME Equities LLC made a charitable donation
of 87,778 of its shares to Ballantyne Jewish Center, Inc. Upon the closing of the Rights Offering, we issued an aggregate of 2,442,468
shares of our Common Stock and received aggregate net proceeds of $246,201, after giving effect to the Representative Affiliate
Transactions, which we used primarily for general corporate purposes and expenses associated with our IPO.

100 

On
December 23, 2023, we entered into the Benuvia License Agreement for the Spray Formulations, diversifying our pipeline of non-opioid
pain treatment therapies, while adding therapeutic options for related conditions. The Diclofenac Spray Formulation is patented
and has started clinical development in human volunteers. Preliminary pharmacokinetics suggest that this formulation may have
a faster onset of action than oral Diclofenac tablets. Diclofenac is an NSAID that is also marketed under additional brand names
including Voltaren and Cataflam in its pill form. Rizatriptan, whose brand name is Maxalt, is used for the acute treatment of
migraines as a pill. By a number of clinical measures it is thought to be superior to Sumatriptan. A sublingual formulation of
Rizatriptan may potentially have a faster onset of action than an oral form and may be easier to tolerate than swallowing a pill
when patients are experiencing nausea as a result of the migraine headache. Ondansetron is an anti-emetic that is available in
oral and intravenous form. An Ondansetron sublingual spray formulation may potentially have a faster onset of action than an oral
form and may be